Advertisement
Open Access 12-03-2025 | Original Research Article
Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint
Published in: Drug Safety
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): module XVI—risk minimisation measures: selection of tools and 5 effectiveness indicators—Draft for Public Consultation (Rev 3) 2021 Nov 20, 2023. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-selection-tools_en.pdf.
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): module XVI—risk minimisation measures: selection of tools and 5 effectiveness indicators—Draft for Public Consultation (Rev 3) 2021 Nov 20, 2023. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-xvi-risk-minimisation-measures-selection-tools_en.pdf.
2.
go back to reference Food and Drug Administration. Risk evaluation and mitigation strategies assessment: planning and reporting; draft guidance for industry; availability 2019 [1153–5] 2019 Nov 20, 2023. Available from: https://www.govinfo.gov/content/pkg/FR-2019-02-01/pdf/2019-00676.pdf.
Food and Drug Administration. Risk evaluation and mitigation strategies assessment: planning and reporting; draft guidance for industry; availability 2019 [1153–5] 2019 Nov 20, 2023. Available from: https://www.govinfo.gov/content/pkg/FR-2019-02-01/pdf/2019-00676.pdf.
3.
go back to reference European Commission. The rules governing medicinal products in the European Union. Volume 9A: guidelines on pharmacovigilance for medicinal products for human use 2008. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf.
European Commission. The rules governing medicinal products in the European Union. Volume 9A: guidelines on pharmacovigilance for medicinal products for human use 2008. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf.
4.
go back to reference Food and Drug Administration. Format and content of a REMS document guidance for industry 2023 May 28, 2024. Available from: https://www.fda.gov/media/77846/download.
Food and Drug Administration. Format and content of a REMS document guidance for industry 2023 May 28, 2024. Available from: https://www.fda.gov/media/77846/download.
5.
go back to reference Food and Drug Administration. REMS logic model: a framework to link program design with assessment; draft guidance for industry 2024. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-logic-model-framework-link-program-design-assessment.
Food and Drug Administration. REMS logic model: a framework to link program design with assessment; draft guidance for industry 2024. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rems-logic-model-framework-link-program-design-assessment.
6.
go back to reference Sarpatwari A, Mitra-Majumdar M, Bykov K, Avorn J, Woloshin S, Toyserkani GA, et al. A multi-modal approach to evaluate the impact of risk evaluation and mitigation strategy (REMS) programs. Drug Saf. 2021;44(7):743–51.PubMedCrossRef
Sarpatwari A, Mitra-Majumdar M, Bykov K, Avorn J, Woloshin S, Toyserkani GA, et al. A multi-modal approach to evaluate the impact of risk evaluation and mitigation strategy (REMS) programs. Drug Saf. 2021;44(7):743–51.PubMedCrossRef
7.
go back to reference Bahri P. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf. 2010;33(12):1065–79.PubMedCrossRef
Bahri P. Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies. Drug Saf. 2010;33(12):1065–79.PubMedCrossRef
8.
go back to reference Morrato EH, Smith MY. Dissemination and implementation science. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Berlin: Springer; 2020. p. 385–413.CrossRef
Morrato EH, Smith MY. Dissemination and implementation science. In: Bahri P, editor. Communicating about risks and safe use of medicines: real life and applied research. Berlin: Springer; 2020. p. 385–413.CrossRef
9.
go back to reference Smith MY, Hogan SA, Jack SM, Wilson RT, Oremus M. The case for using mixed methods for designing, implementing, and disseminating evidence-based interventions for public health practice. J Public Health Policy. 2022;43(2):292–303.PubMedCrossRef
Smith MY, Hogan SA, Jack SM, Wilson RT, Oremus M. The case for using mixed methods for designing, implementing, and disseminating evidence-based interventions for public health practice. J Public Health Policy. 2022;43(2):292–303.PubMedCrossRef
10.
go back to reference Nilsen P. Making sense of implementation theories, models and frameworks. Implement Sci. 2015;10:53.PubMedPubMedCentralCrossRef
Nilsen P. Making sense of implementation theories, models and frameworks. Implement Sci. 2015;10:53.PubMedPubMedCentralCrossRef
11.
go back to reference Morrato EH. Social science theory as a framework for designing and evaluating pharmaceutical risk management dissemination and implementation Strategies. In: Sprafka JM, editor. Risk management principles for devices and pharmaceuticals. 3rd ed. Rockville: Regulatory Affairs Professionals Society; 2023.
Morrato EH. Social science theory as a framework for designing and evaluating pharmaceutical risk management dissemination and implementation Strategies. In: Sprafka JM, editor. Risk management principles for devices and pharmaceuticals. 3rd ed. Rockville: Regulatory Affairs Professionals Society; 2023.
12.
go back to reference Huynh L, Toyserkani GA, Morrato EH. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA risk evaluation and mitigation strategies (REMS) (2014–2018). BMC Health Serv Res. 2021;21(1):779.PubMedPubMedCentralCrossRef
Huynh L, Toyserkani GA, Morrato EH. Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA risk evaluation and mitigation strategies (REMS) (2014–2018). BMC Health Serv Res. 2021;21(1):779.PubMedPubMedCentralCrossRef
13.
go back to reference Toyserkani GA, Huynh L, Morrato EH. Adaptation for regulatory application: a content analysis of FDA risk evaluation and mitigation strategies assessment plans (2014–2018) using RE-AIM. Front Public Health. 2020;8:43.PubMedPubMedCentralCrossRef
Toyserkani GA, Huynh L, Morrato EH. Adaptation for regulatory application: a content analysis of FDA risk evaluation and mitigation strategies assessment plans (2014–2018) using RE-AIM. Front Public Health. 2020;8:43.PubMedPubMedCentralCrossRef
14.
go back to reference Birken SA, Rohweder CL, Powell BJ, Shea CM, Scott J, Leeman J, et al. T-CaST: an implementation theory comparison and selection tool. Implement Sci. 2018;13(1):143.PubMedPubMedCentralCrossRef
Birken SA, Rohweder CL, Powell BJ, Shea CM, Scott J, Leeman J, et al. T-CaST: an implementation theory comparison and selection tool. Implement Sci. 2018;13(1):143.PubMedPubMedCentralCrossRef
15.
go back to reference Strifler L, Barnsley JM, Hillmer M, Straus SE. Identifying and selecting implementation theories, models and frameworks: a qualitative study to inform the development of a decision support tool. BMC Med Inform Decis Mak. 2020;20(1):91.PubMedPubMedCentralCrossRef
Strifler L, Barnsley JM, Hillmer M, Straus SE. Identifying and selecting implementation theories, models and frameworks: a qualitative study to inform the development of a decision support tool. BMC Med Inform Decis Mak. 2020;20(1):91.PubMedPubMedCentralCrossRef
16.
go back to reference Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci. 2022;17(1):75.PubMedPubMedCentralCrossRef
Damschroder LJ, Reardon CM, Widerquist MAO, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci. 2022;17(1):75.PubMedPubMedCentralCrossRef
17.
go back to reference Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–7.PubMedPubMedCentralCrossRef
Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–7.PubMedPubMedCentralCrossRef
18.
go back to reference Feldstein AC, Glasgow RE. A Practical, Robust Implementation and Sustainability Model (PRISM) for integrating research findings into practice. Jt Commun J Qual Patient Saf. 2008;34(4):228–43.
Feldstein AC, Glasgow RE. A Practical, Robust Implementation and Sustainability Model (PRISM) for integrating research findings into practice. Jt Commun J Qual Patient Saf. 2008;34(4):228–43.
19.
go back to reference Green LW, Kreuter MW. Health program planning: an educational and ecological approach. 4th ed. New York: McGraw-Hill; 2005.
Green LW, Kreuter MW. Health program planning: an educational and ecological approach. 4th ed. New York: McGraw-Hill; 2005.
20.
go back to reference Smith MY, Morrato E. Advancing the field of pharmaceutical risk minimization through application of implementation science best practices. Drug Saf. 2014;37(8):569–80.PubMedPubMedCentralCrossRef
Smith MY, Morrato E. Advancing the field of pharmaceutical risk minimization through application of implementation science best practices. Drug Saf. 2014;37(8):569–80.PubMedPubMedCentralCrossRef
21.
go back to reference Sanofi. Depakote (valproate) summary of product characteristics 2021. https://www.medicines.org.uk/emc/product/6102/smpc#gref.
Sanofi. Depakote (valproate) summary of product characteristics 2021. https://www.medicines.org.uk/emc/product/6102/smpc#gref.
22.
go back to reference European Medicines Agency. Valproate and related substances [EU referral procedure in 2014] 2014. https://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Valproate_and_related_substances/humanreferral_prac_00003.
European Medicines Agency. Valproate and related substances [EU referral procedure in 2014] 2014. https://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Valproate_and_related_substances/humanreferral_prac_00003.
23.
go back to reference Ehlken B, Nishikawa C, Kaplan S, Dresco I, Granados D, Toussi M. Effectiveness of risk minimization measures for valproate: a drug utilization study based on implementation of a risk minimization programme in Europe, analysis of data from the UK. Curr Med Res Opin. 2022;38(3):461–8.PubMedCrossRef
Ehlken B, Nishikawa C, Kaplan S, Dresco I, Granados D, Toussi M. Effectiveness of risk minimization measures for valproate: a drug utilization study based on implementation of a risk minimization programme in Europe, analysis of data from the UK. Curr Med Res Opin. 2022;38(3):461–8.PubMedCrossRef
24.
go back to reference Valproate banned without the pregnancy prevention programme [press release]. 2018.
Valproate banned without the pregnancy prevention programme [press release]. 2018.
25.
go back to reference Pharmacovigilance Risk Assessment Committee. PRAC recommends new measures to avoid valproate exposure in pregnancy: new restrictions on use; pregnancy prevention programme to be put in place 2018 Dec 4, 2023. Available from: https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-prac-recommends-new-measures-avoid-valproate-exposure-pregnancy_en.pdf.
Pharmacovigilance Risk Assessment Committee. PRAC recommends new measures to avoid valproate exposure in pregnancy: new restrictions on use; pregnancy prevention programme to be put in place 2018 Dec 4, 2023. Available from: https://www.ema.europa.eu/en/documents/referral/valproate-article-31-referral-prac-recommends-new-measures-avoid-valproate-exposure-pregnancy_en.pdf.
26.
go back to reference European Medicines Agency. Public hearing on valproate: first experience and lessons learnt 2017 June 2, 2020. Available from: https://www.ema.europa.eu/en/documents/report/public-hearing-valproate-first-experience-and-lessons-learnt_en.pdf.
European Medicines Agency. Public hearing on valproate: first experience and lessons learnt 2017 June 2, 2020. Available from: https://www.ema.europa.eu/en/documents/report/public-hearing-valproate-first-experience-and-lessons-learnt_en.pdf.
27.
go back to reference Bahri P, Morales DR, Inoubli A, Dogné JM, Straus S. Proposals for engaging patients and healthcare professionals in risk minimisation from an analysis of stakeholder input to the EU valproate assessment using the novel Analysing Stakeholder Safety Engagement Tool (ASSET). Drug Saf. 2021;44(2):193–209.PubMedCrossRef
Bahri P, Morales DR, Inoubli A, Dogné JM, Straus S. Proposals for engaging patients and healthcare professionals in risk minimisation from an analysis of stakeholder input to the EU valproate assessment using the novel Analysing Stakeholder Safety Engagement Tool (ASSET). Drug Saf. 2021;44(2):193–209.PubMedCrossRef
28.
go back to reference Creswell J, Plano C, V L, Guttman M, Hanson W. Advanced mixed methods research designs. In: Tashakkori A, Teddlie C, editors. Handbook on mixed methods in the behavioral and social sciences. Thousand Oaks: Sage Publications; 2003. p. 209-40.
Creswell J, Plano C, V L, Guttman M, Hanson W. Advanced mixed methods research designs. In: Tashakkori A, Teddlie C, editors. Handbook on mixed methods in the behavioral and social sciences. Thousand Oaks: Sage Publications; 2003. p. 209-40.
29.
go back to reference Creswell JW, Plano Clark VL. Designing and conducting mixed methods research. 2nd ed. Thousand Oaks: Sage Publications; 2011.
Creswell JW, Plano Clark VL. Designing and conducting mixed methods research. 2nd ed. Thousand Oaks: Sage Publications; 2011.
30.
go back to reference Palinkas LA, Mendon SJ, Hamilton AB. Innovations in mixed methods evaluations. Annu Rev Public Health. 2019;40:423–42.PubMedPubMedCentralCrossRef
Palinkas LA, Mendon SJ, Hamilton AB. Innovations in mixed methods evaluations. Annu Rev Public Health. 2019;40:423–42.PubMedPubMedCentralCrossRef
31.
go back to reference Barbour RS. The case for combining qualitative and quantitative approaches in health services research. J Health Serv Res Policy. 1999;4(1):39–43.PubMedCrossRef
Barbour RS. The case for combining qualitative and quantitative approaches in health services research. J Health Serv Res Policy. 1999;4(1):39–43.PubMedCrossRef
32.
go back to reference Artime E, Qizilbash N, Garrido-Estepa M, Vora P, Soriano-Gabarró M, Asiimwe A, Pocock S. Are risk minimization measures for approved drugs in Europe effective? A systematic review. Expert Opin Drug Saf. 2019;18(5):443–54.PubMedCrossRef
Artime E, Qizilbash N, Garrido-Estepa M, Vora P, Soriano-Gabarró M, Asiimwe A, Pocock S. Are risk minimization measures for approved drugs in Europe effective? A systematic review. Expert Opin Drug Saf. 2019;18(5):443–54.PubMedCrossRef
33.
go back to reference Gridchyna I, Cloutier AM, Nkeng L, Craig C, Frise S, Moride Y. Methodological gaps in the assessment of risk minimization interventions: a systematic review. Pharmacoepidemiol Drug Saf. 2014;23(6):572–9.PubMedCrossRef
Gridchyna I, Cloutier AM, Nkeng L, Craig C, Frise S, Moride Y. Methodological gaps in the assessment of risk minimization interventions: a systematic review. Pharmacoepidemiol Drug Saf. 2014;23(6):572–9.PubMedCrossRef
34.
go back to reference Grupstra RJ, Goedecke T, Scheffers J, Strassmann V, Gardarsdottir H. Review of studies evaluating effectiveness of risk minimization measures assessed by the European Medicines Agency between 2016 and 2021. Clin Pharmacol Ther. 2023;114(6):1285–92.PubMedCrossRef
Grupstra RJ, Goedecke T, Scheffers J, Strassmann V, Gardarsdottir H. Review of studies evaluating effectiveness of risk minimization measures assessed by the European Medicines Agency between 2016 and 2021. Clin Pharmacol Ther. 2023;114(6):1285–92.PubMedCrossRef
35.
go back to reference Levinson DR. FDA lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drug safety. HHS Office of Inspector General [Internet]. 2013:1–38. Available from: https://oig.hhs.gov/oei/reports/oei-04-11-00510.pdf.
Levinson DR. FDA lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drug safety. HHS Office of Inspector General [Internet]. 2013:1–38. Available from: https://oig.hhs.gov/oei/reports/oei-04-11-00510.pdf.
36.
go back to reference Mazzaglia G, Straus SMJ, Arlett P, da Silva D, Janssen H, Raine J, Alteri E. Study design and evaluation of risk minimization measures: a review of studies submitted to the European Medicines Agency for cardiovascular, endocrinology, and metabolic drugs. Drug Saf. 2018;41(2):191–202.PubMedCrossRef
Mazzaglia G, Straus SMJ, Arlett P, da Silva D, Janssen H, Raine J, Alteri E. Study design and evaluation of risk minimization measures: a review of studies submitted to the European Medicines Agency for cardiovascular, endocrinology, and metabolic drugs. Drug Saf. 2018;41(2):191–202.PubMedCrossRef
37.
go back to reference Okai J, Bahri P, Sarinic VM. Reporting quality of evaluations of additional risk minimisation measures by MAH: an assessment of studies submitted in the European Union. Drug Saf. 2021;44(12):1402–3.
Okai J, Bahri P, Sarinic VM. Reporting quality of evaluations of additional risk minimisation measures by MAH: an assessment of studies submitted in the European Union. Drug Saf. 2021;44(12):1402–3.
38.
go back to reference Prieto L, Spooner A, Hidalgo-Simon A, Rubino A, Kurz X, Arlett P. Evaluation of the effectiveness of risk minimization measures. Pharmacoepidemiol Drug Saf. 2012;21(8):896–9.PubMedCrossRef
Prieto L, Spooner A, Hidalgo-Simon A, Rubino A, Kurz X, Arlett P. Evaluation of the effectiveness of risk minimization measures. Pharmacoepidemiol Drug Saf. 2012;21(8):896–9.PubMedCrossRef
39.
go back to reference Russell AM, Morrato EH, Lovett RM, Smith MY. Quality of reporting on the evaluation of risk minimization programs: a systematic review. Drug Saf. 2020;43(5):427–46.PubMedCrossRef
Russell AM, Morrato EH, Lovett RM, Smith MY. Quality of reporting on the evaluation of risk minimization programs: a systematic review. Drug Saf. 2020;43(5):427–46.PubMedCrossRef
40.
go back to reference Farcas A, Huruba M, Mogosan C. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register. Br J Clin Pharmacol. 2019;85(3):476–91.PubMedCrossRef
Farcas A, Huruba M, Mogosan C. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register. Br J Clin Pharmacol. 2019;85(3):476–91.PubMedCrossRef
41.
go back to reference European Medicines Agency. HMA-EMA catalogues of real-world data sources and studies 2024. https://catalogues.ema.europa.eu/.
European Medicines Agency. HMA-EMA catalogues of real-world data sources and studies 2024. https://catalogues.ema.europa.eu/.
42.
go back to reference Toyserkani GA, Ewusie SB, Turk P, Quick J, Morrato EH. Evolution of cross-sectional survey protocol quality over time: a case series of index US REMS Knowledge Survey Protocols (2007–2020). Drug Saf. 2023;46(11):1073–87.PubMedCrossRef
Toyserkani GA, Ewusie SB, Turk P, Quick J, Morrato EH. Evolution of cross-sectional survey protocol quality over time: a case series of index US REMS Knowledge Survey Protocols (2007–2020). Drug Saf. 2023;46(11):1073–87.PubMedCrossRef
43.
go back to reference Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64.PubMedPubMedCentralCrossRef
Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7:64.PubMedPubMedCentralCrossRef
44.
go back to reference Rabin BA, Cakici J, Golden CA, Estabrooks PA, Glasgow RE, Gaglio B. A citation analysis and scoping systematic review of the operationalization of the Practical, Robust Implementation and Sustainability Model (PRISM). Implement Sci. 2022;17(1):62.PubMedPubMedCentralCrossRef
Rabin BA, Cakici J, Golden CA, Estabrooks PA, Glasgow RE, Gaglio B. A citation analysis and scoping systematic review of the operationalization of the Practical, Robust Implementation and Sustainability Model (PRISM). Implement Sci. 2022;17(1):62.PubMedPubMedCentralCrossRef
45.
go back to reference Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions—systematic review and methodological considerations. Br J Clin Pharmacol. 2018;84(3):419–33.PubMedCrossRef
Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions—systematic review and methodological considerations. Br J Clin Pharmacol. 2018;84(3):419–33.PubMedCrossRef
46.
go back to reference Pharmacovigilance Risk Assessment Committee. PRAC strategy on measuring the impact of pharmacovigilance activities (EMA/790863/2015) 2017 Aug 1, 2017. Available from: https://www.ema.europa.eu/en/documents/report/report-workshop-measuring-impact-pharmacovigilance-activities_en.pdf.
Pharmacovigilance Risk Assessment Committee. PRAC strategy on measuring the impact of pharmacovigilance activities (EMA/790863/2015) 2017 Aug 1, 2017. Available from: https://www.ema.europa.eu/en/documents/report/report-workshop-measuring-impact-pharmacovigilance-activities_en.pdf.
47.
go back to reference Haynes A, Loblay V. Rethinking barriers and enablers in qualitative health research: Limitations, alternatives and enhancements. Qualitative Health Research 2024;34(14):1371–83.
Haynes A, Loblay V. Rethinking barriers and enablers in qualitative health research: Limitations, alternatives and enhancements. Qualitative Health Research 2024;34(14):1371–83.
48.
go back to reference Thompson W. Deprescribing: Moving beyond barriers and facilitators. Res in Soc Admin Pharm 2022;18(3):2547–9.
Thompson W. Deprescribing: Moving beyond barriers and facilitators. Res in Soc Admin Pharm 2022;18(3):2547–9.
49.
go back to reference Wu J, Juhaeri J. The US Food and Drug Administration’s risk evaluation and mitigation strategy (REMS) program—current status and future direction. Clin Ther. 2016;38(12):2526–32.PubMedCrossRef
Wu J, Juhaeri J. The US Food and Drug Administration’s risk evaluation and mitigation strategy (REMS) program—current status and future direction. Clin Ther. 2016;38(12):2526–32.PubMedCrossRef
50.
go back to reference Forman J, Heisler M, Damschroder LJ, Kaselitz E, Kerr EA. Development and application of the RE-AIM QuEST mixed methods framework for program evaluation. Prev Med Rep. 2017;6:322–8.PubMedPubMedCentralCrossRef
Forman J, Heisler M, Damschroder LJ, Kaselitz E, Kerr EA. Development and application of the RE-AIM QuEST mixed methods framework for program evaluation. Prev Med Rep. 2017;6:322–8.PubMedPubMedCentralCrossRef
51.
go back to reference REMS assessment: planning and reporting. Guidance for Industry Food and Drug Administration 2019. https://www.fda.gov/media/119790/download. Accessed Feb 4.
REMS assessment: planning and reporting. Guidance for Industry Food and Drug Administration 2019. https://www.fda.gov/media/119790/download. Accessed Feb 4.
52.
go back to reference Smith MY, Morrato EH, Mora N, Nguyen V, Pinnock H, Winterstein AG. The reporting recommendations intended for pharmaceutical risk minimization evaluation studies: standards for reporting of implementation studies extension (RIMES-SE). Drug Saf. 2024;47(7):655–71.PubMedPubMedCentralCrossRef
Smith MY, Morrato EH, Mora N, Nguyen V, Pinnock H, Winterstein AG. The reporting recommendations intended for pharmaceutical risk minimization evaluation studies: standards for reporting of implementation studies extension (RIMES-SE). Drug Saf. 2024;47(7):655–71.PubMedPubMedCentralCrossRef
53.
go back to reference Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, et al. Standards for reporting implementation studies (StaRI) statement. BMJ. 2017;356: i6795.PubMedPubMedCentralCrossRef
Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, et al. Standards for reporting implementation studies (StaRI) statement. BMJ. 2017;356: i6795.PubMedPubMedCentralCrossRef
54.
go back to reference Bahri P, Genov G, Arlett P, Šarinić VM, Korakianiti E, Nolte A, et al. The STAR Compass to guide future pharmacovigilance based on a 10-year review of the strengthened EU system. Drug Saf. 2024;47:941–56.PubMedPubMedCentralCrossRef
Bahri P, Genov G, Arlett P, Šarinić VM, Korakianiti E, Nolte A, et al. The STAR Compass to guide future pharmacovigilance based on a 10-year review of the strengthened EU system. Drug Saf. 2024;47:941–56.PubMedPubMedCentralCrossRef
Metadata
- Title
- Using Mixed Methods to Evaluate Risk Minimisation Programs in Europe and the USA: An Innovative Blueprint
- Authors
-
Meredith Y. Smith
Rachel Davis
Priya Bahri
Delphine Saragoussi
Viviana Nguyen
Gita A. Toyserkani
Alison Hamilton
- Publication date
- 12-03-2025
- Publisher
- Springer International Publishing
- Published in
-
Drug Safety
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942 - DOI
- https://doi.org/10.1007/s40264-025-01533-w